β3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival

Journal of Clinical Investigation

Volumn 103, Issue 2, 1999, Pages 229-238

  Hodivala Dilke, Kairbaan M ^a   McHugh, Kevin P ^b   Tsakiris, Dimitrios A ^c   Rayburn, Helen ^a   Crowley, Denise ^a   Ullman Culleré, Mollie ^a   Ross, F Patrick ^b   Coller, Barry S ^c   Teitelbaum, Steven ^b   Hynes, Richard O ^a,d  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRIN; BETA3 INTEGRIN; FIBRINOGEN RECEPTOR; LEUKOCYTE ANTIGEN;

ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING TIME; BLOOD CLOT RETRACTION; CONTROLLED STUDY; FEMALE; GASTROINTESTINAL HEMORRHAGE; GENETIC DISORDER; GLANZMANN DISEASE; MOUSE; MOUSE STRAIN; NONHUMAN; PLACENTA DISORDER; PRIORITY JOURNAL; RETINA NEOVASCULARIZATION; SURVIVAL; THROMBOCYTE AGGREGATION; ANIMAL; BLEEDING; CONGENITAL MALFORMATION; DIGESTIVE SYSTEM; DISEASE MODEL; ERYTHROCYTE COUNT; FETUS; FLUORESCENT ANTIBODY TECHNIQUE; GENE TARGETING; GENETICS; LEUKOCYTE COUNT; METABOLISM; METHODOLOGY; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; UTERUS;

ANIMALS; ANTIGENS, CD; BLEEDING TIME; DIGESTIVE SYSTEM; DISEASE MODELS, ANIMAL; ERYTHROCYTE COUNT; FEMALE; FETUS; FLUORESCENT ANTIBODY TECHNIQUE; GENE TARGETING; HEMORRHAGE; INTEGRIN BETA3; INTEGRINS; LEUKOCYTE COUNT; MICE; MICE, KNOCKOUT; PLATELET AGGREGATION; PLATELET MEMBRANE GLYCOPROTEINS; THROMBASTHENIA; UTERUS;

EID: 0032590042     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI5487     Document Type: Article

References (49)

1. Hynes, R.O. 1992. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 69:11-25.
2. Kieffer, N., and Phillips, D.R. 1990. Platelet membrane glycoproteins: functions in cellular interactions. Annu. Rev. Cell Biol. 6:329-357.
3. Shattil, S.J. 1995. Function and regulation of the β3 integrins in hemostasis and vascular biology. Thromb. Haemost. 74:149-155.
4. Du, X., and Ginsberg, M.H 1997. Integrin αIIbβ3 and platelet function. Thromb. Haemost. 78:96-100.
5. Lawler, J., Weinstein, R., and Hynes, R.O. 1988. Cell attachment to thrombospondin: the role of ARG-GLY-ASP, calcium, and integrin receptors. J. Cell Biol. 107:2351-2361.
6. Engleman, V.W., et al. 1997. A peptidomimetic antagonist of the alpha(v)beta3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J. Clin. Invest. 99:2284-2292.
7. Albelda, S.M., et al. 1990. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res. 20:6757-6764.
8. Cheresh, D.A., and Harper, J.R. 1987. Arg-Gly-Asp recognition by a cell adhesion receptor requires its 130-kDa alpha subunit. J. Biol. Chem. 262:1434-1437.
9. Felding-Habermann, B., and Cheresh, D.A. 1993. Vitronectin and its receptors. Curr. Opin. Cell. Biol. 5:864-868.
10. Stefansson, S., and Lawrence, D.A. 1996. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin [comment]. Nature. 383:441-443.
11. Yip, P.M., Zhao, X., Montgomery, A.M., and Siu, C.H. 1998. The Arg-Gly-Asp motif in the cell adhesion molecule L1 promotes neunte outgrowth via interaction with the alphavbeta3 integrin. Mol. Biol. Cell. 9:277-290.
12. Montgomery, A.M., et al. 1996. Human neural cell adhesion molecule L1 and rat homologue NILE are ligands for integrin alpha v beta 3. J. Cell. Biol. 132:475-485.
13. Brooks, P.C., Silletti, S., von Schalscha, T.L., Friedlander, M., and Cheresh, D.A. 1998. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell. 92:391-400.
14. Coller, B.S. 1995. Hereditary qualitative platelet disorders. In William's hematology. 5th ed. McGraw-Hill. New York, NY. 1364-1385.
15. Coller, B.S., Seligsohn, U., and Little, P.A. 1987. Type I Glanzmann thrombasthenia patients from the Iraqi-Jewish and Arab populations in Israel can be differentiated by platelet glycoprotein IIIa immunoblot analysis. Blood. 69:1696-1703.
16. Sutherland, A.E., Calarco, P.G., and Damsky, C.H. 1993. Developmental regulation of integrin expression at the time of implantation in the mouse embryo. Development. 119:1175-1186.
17. Korpelainen, E.I., and Alitalo, K. 1998. Signaling angiogenesis and lymphangiogenesis. Curr. Opin. Cell. Biol. 10:159-164.
18. Hanahan, D., and Folkman, J. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353-364.
19. Varner, J.A., and Cheresh, D.A. 1996. Integrins and cancer. Curr. Opin. Cell. Biol. 8:724-730.
20. Brooks, P.C., et al. 1995. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96:1815-1822.
21. Brooks, P.C., et al. 1996. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell. 85:683-693.
22. Drake, C., Cheresh, D., and Little, C. 1995. An antagonist of integrin alphavbeta3 prevents maturation of blood vessels during embryonic neovascularization. J. Cell. Sci 108:2655-2661.
23. Friedlander, M., et al. 1996. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc. Natl. Acad. Sci. USA. 93:9764-9769.
24. Hammes, H.P., Brownlee, M., Jonczyk, A., Sutter, A., and Preissner, K.T. 1996. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat. Med. 2:529-533.
25. Crippes, B.A., et al. 1996 Antibody to β3 integrin inhibits osteoclast-mediated bone resorption in the thyroparathyroidectomized rat. Endocrinology. 137:918-924.
26. Horton, M.A., Taylor, M.L., Arnett, T.R. and Helfrich, M.H. 1991. Arg-gly-asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts. Exp. Cell Res. 195:368-375.
27. Ross, F.P., et al. 1993. Interactions between the bone matrix proteins osteopontin and bone sialoprotein and the osteoclas: integrin αvβ3 potentiate bone resorption. J. Biol. Chem. 268:9901-9907.
28. Marcantonio, E.E., and Hynes, R.O. 1988. Antibodies to the conserved cytoplasmic domain of the integrin beta 1 subunit react with proteins in vertebrates, invertebrates, and fungi. J. Cell Biol. 106:1765-1772.
29. Hynes, R.O., et al. 1989. Integrin heterodimer and receptor complexity in avian and mammalian cells. J. Cell Biol. 109:409-420.
30. DiPersio, C., Shah, S., and Hynes, R 1995. alpha3 beta1 integrin localizes to focal contacts in response to diverse extracellular matrix proteins. J. Cell. Sci. 108:2321-2336.
31. George, E.L., et al. 1993. Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development, 119:1079-1091.
32. George, E.L., and Hynes, R.O. 1994. Gene targeting and generation of mutant mice for studies of cell-extracellular matrix interactions. Methods Enzymol 245:386-420.
33. Frenette, P.S., Johnson, R.C., Hynes, R.O., and Wagner, D.D. 1995. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc. Natl. Acad. Sci. USA. 92:7450-7454.
34. Beer, J.H. and Coller, B.S. 1989. Evidence that platelet glycoprotein IIIa has a large disulfide bonded loop that is susceptible to proteolytic cleavage. J. Biol. Chem. 264:17564-17573.
35. Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:680-685.
36. Dejana, E., Quintana, A., Callioni, A., and de Gaetano, G. 1979. Bleeding time in laboratory animals. III - Do tail bleeding times in rats only measure a platelet defect? (the aspirin puzzle). Thromb. Res. 15:199-207.
37. Subramaniam, M., et al. 1996. Defects in hemostasis in P-selectin-deficient mice. Blood. 87:1238-1242.
38. Bronza, J.P. 1990. Shwartzman reaction. Semin. Thromb. Hemost. 16:326-332.
39. Hogan, B., Beddington, R., Constantini, F., and Lacy, E. 1994. Manipulating the mouse embryo. 2nd ed. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, NY. 258-259.
40. D'Amato, R., Wesolowski, E., and Smith, L.E. 1993. Microscopic visualization of the retina by angiography with high-molecular-weight fluorescein-labeled dextrans in the mouse. Microvasc. Res. 46:135-142.
41. Coller, B. S., Cheresh, D. A., Asch, E., and Seligsohn, U. 1991. Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel. Blood. 77:75-83.
42. French, D.L., and Coller, B.S. 1997. Hematologically important mutations: Glanzmann thrombasthenia. Blood Cells Mol. Dis. 23:39-51.
43. Denis C., et al. 1998. A model of severe von Willebrand disease: Defects in hemostasis and thrombosis. Proc. Natl. Acad. Sci. USA. 95:9524-9529.
44. Bader, B.L., Rayburn, H., Crowley, D., and Hynes, R.O. 1998. Extensive vasculogenesis, angiogenesis and organogenesis precede lethality in mice lacking all αv integrins. Cell. 95:507-519.
45. Zhou, Y., Damsky, C.H., and Fisher, S.J. 1997. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J. Clin. Invest. 99:2152-2164.
46. Zhou, Y., et al. 1997. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion?. J. Clin. Invest. 99:2139-2151.
47. Sepp, N.T., et al. 1994. Basic fibroblast growth factor increases expression of the alpha v beta 3 integrin complex on human microvascular endothelial cells. J. Invest. Dermatol. 103:295-299.
48. Panda, D., et al. 1997. Potential roles of osteopontin and αvβ3 integrin in the development of coronary artery restenosis after angioplasty. Proc. Natl. Acad. Sci. USA. 94:9308-9313.
49. Li, C.F., Ross, F.P., Cao, X., and Teitelbaum, S.L. 1995. Estrogen enhances alpha v beta 3 integrin expression by avian osteoclast precursors via stabilization of beta 3 integrin mRNA. Mol. Endocrinol 9:805-813.